Thomas Harth

Thomas joined Gimv in 2017 and is Associate within the Health & Care team working out of the Antwerp office. He is focusing on early stage Life Sciences investments. Thomas is involved in Kinaset Therapeutics, Fire1, ONWARD, Biotalys and JenaValve and previously in Breath Therapeutics, successfully sold to Zambon.

Thomas holds a Masters degree in Bioengineering and Applied Economics, both from the University of Ghent.